Cargando…
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
BACKGROUND: Levels of 50% neutralizing titer (NT50) reflect the a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627865/ https://www.ncbi.nlm.nih.gov/pubmed/34857462 http://dx.doi.org/10.1016/j.jiac.2021.11.021 |
_version_ | 1784606901624897536 |
---|---|
author | Kato, Hideaki Miyakawa, Kei Ohtake, Norihisa Go, Hirofumi Yamaoka, Yutaro Yajima, Satoshi Shimada, Tomoko Goto, Atsushi Nakajima, Hideaki Ryo, Akihide |
author_facet | Kato, Hideaki Miyakawa, Kei Ohtake, Norihisa Go, Hirofumi Yamaoka, Yutaro Yajima, Satoshi Shimada, Tomoko Goto, Atsushi Nakajima, Hideaki Ryo, Akihide |
author_sort | Kato, Hideaki |
collection | PubMed |
description | BACKGROUND: Levels of 50% neutralizing titer (NT50) reflect the a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is expected for determining the level of herd immunity against SARS-CoV-2. METHODS: We analyzed samples from 168 Japanese healthcare workers who had completed two doses of the BNT162b2 vaccine. We analyzed immunoglobulin G (IgG) index values against spike protein (SP) using automated chemiluminescent enzyme immunoassay system AIA-CL and analyzed the background factors affecting antibody titer. SP IgG index was compared with 50% neutralization titers. RESULTS: The median SP IgG index values of the subjects (mean age = 43 years; 75% female) were 0.1, 1.35, 60.80, and 97.35 before and at 2, 4, and 6 weeks after the first dose, respectively. At 4 and 6 weeks after the first dose, SP IgG titers were found to have positive correlation with NT50 titer (r = 0.7535 in 4 weeks; r = 0.4376 in 6 weeks). Proportions of the SP IgG index values against the Alpha, Beta, Gamma, and Delta variants compared with the original strain were 2.029, 0.544, 1.017, and 0.6096 respectively. Older age was associated with lower SP IgG titer index 6 weeks after the first dose. CONCLUSIONS: SP IgG index values were rised at 3 weeks after two doses of BNT162b2 vaccination and have positive correlation with NT50. SP IgG index values were lower in the older individuals and against Beta and Delta strain. |
format | Online Article Text |
id | pubmed-8627865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86278652021-11-29 Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay Kato, Hideaki Miyakawa, Kei Ohtake, Norihisa Go, Hirofumi Yamaoka, Yutaro Yajima, Satoshi Shimada, Tomoko Goto, Atsushi Nakajima, Hideaki Ryo, Akihide J Infect Chemother Original Article BACKGROUND: Levels of 50% neutralizing titer (NT50) reflect the a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is expected for determining the level of herd immunity against SARS-CoV-2. METHODS: We analyzed samples from 168 Japanese healthcare workers who had completed two doses of the BNT162b2 vaccine. We analyzed immunoglobulin G (IgG) index values against spike protein (SP) using automated chemiluminescent enzyme immunoassay system AIA-CL and analyzed the background factors affecting antibody titer. SP IgG index was compared with 50% neutralization titers. RESULTS: The median SP IgG index values of the subjects (mean age = 43 years; 75% female) were 0.1, 1.35, 60.80, and 97.35 before and at 2, 4, and 6 weeks after the first dose, respectively. At 4 and 6 weeks after the first dose, SP IgG titers were found to have positive correlation with NT50 titer (r = 0.7535 in 4 weeks; r = 0.4376 in 6 weeks). Proportions of the SP IgG index values against the Alpha, Beta, Gamma, and Delta variants compared with the original strain were 2.029, 0.544, 1.017, and 0.6096 respectively. Older age was associated with lower SP IgG titer index 6 weeks after the first dose. CONCLUSIONS: SP IgG index values were rised at 3 weeks after two doses of BNT162b2 vaccination and have positive correlation with NT50. SP IgG index values were lower in the older individuals and against Beta and Delta strain. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-02 2021-11-29 /pmc/articles/PMC8627865/ /pubmed/34857462 http://dx.doi.org/10.1016/j.jiac.2021.11.021 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Kato, Hideaki Miyakawa, Kei Ohtake, Norihisa Go, Hirofumi Yamaoka, Yutaro Yajima, Satoshi Shimada, Tomoko Goto, Atsushi Nakajima, Hideaki Ryo, Akihide Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay |
title | Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay |
title_full | Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay |
title_fullStr | Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay |
title_full_unstemmed | Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay |
title_short | Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay |
title_sort | antibody titers against the alpha, beta, gamma, and delta variants of sars-cov-2 induced by bnt162b2 vaccination measured using automated chemiluminescent enzyme immunoassay |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627865/ https://www.ncbi.nlm.nih.gov/pubmed/34857462 http://dx.doi.org/10.1016/j.jiac.2021.11.021 |
work_keys_str_mv | AT katohideaki antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT miyakawakei antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT ohtakenorihisa antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT gohirofumi antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT yamaokayutaro antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT yajimasatoshi antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT shimadatomoko antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT gotoatsushi antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT nakajimahideaki antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay AT ryoakihide antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay |